SIHUAN PHARM (00460) signs a strategic partnership with Biocytogen Pharmaceuticals (02315) to accelerate research and development in various areas including weight loss using an AI-driven fully human antibody development platform.

SIHUAN PHARM (00460) announces that the group has officially signed a strategic cooperation agreement with Biocytogen Pharmaceuticals (Beijing) Medical Technology Co., Ltd. (Stock code: 688796.SH; 02315.HK). The two parties will base their cooperation on the principles of complementary advantages and professional synergy, leveraging the group's mature experience in the full industry chain of drug development, scale production, and commercialization, combined with Biocytogen Pharmaceuticals' leading AI-driven whole human antibody development platform technologies. They will engage in joint research and development of innovative drugs in multiple high-potential disease areas, such as weight loss, aiming to establish a long-term stable and mutually beneficial cooperation relationship and jointly promote the research and commercialization of cutting-edge innovative drugs worldwide. The first collaborative project of this strategic cooperation focuses on the group's research in the new generation of innovative weight loss drugs. This research project aims to break through the industry pain points of current weight loss therapies, achieve safe and efficient energy expenditure improvement through innovative mechanisms, while maintaining and enhancing muscle mass, accurately meeting the clinical needs in the global obesity treatment field that are not yet fully satisfied, and potentially driving the optimization and upgrading of weight loss treatment solutions to boost industry development. The pharmaceutical research and development industry is currently undergoing a deep transformation towards artificial intelligence and efficiency. The deep integration of AI and automation technologies with antibody drug research and development has become an inevitable trend in industry development. The "AI+ high-throughput" research and development model is leading the industry's efficiency revolution, effectively shortening the development cycle of antibody drugs, reducing research and development costs, accelerating the design and selection of globally pioneering new drugs (First-in-Class), and establishing core competitive advantages for innovative pharmaceutical enterprises. The group highly recognizes Biocytogen Pharmaceuticals' technological strength and industry position in AI-driven antibody research, gene editing, and model animal fields. In this cooperation, Biocytogen Pharmaceuticals will fully leverage its independently developed model animal and efficacy evaluation platform, whole human antibody discovery platform, and AI-driven antibody drug development platform's comprehensive technological advantages, providing all-round and high-standard technical support for the collaborative projects to ensure efficient progress.